Study to Assess the Efficacy and Safety of Brolucizumab 6mg Compared to Aflibercept 2 mg in a Treat-to-control Regimen (TALON)
Public ClinicalTrials.gov record NCT04005352. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A 64-week, Two-arm, Randomized, Double-masked, Multicenter, Phase IIIb Study Assessing the Efficacy and Safety of Brolucizumab 6 mg Compared to Aflibercept 2 mg in a Treat-to-control Regimen in Patients With Neovascular Agerelated Macular Degeneration (TALON)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This was a 64-week randomized, double-masked, multi-center, active-controlled, two-arm study in patients with neovascular age related macular degeneration (nAMD) who have not previously received anti- vascular endothelial growth factor (VEGF) treatment.
Study identification
- NCT ID
- NCT04005352
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 734 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 50 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Sep 25, 2019 (Actual)
- Primary completion
- Sep 9, 2022 (Actual)
- Completion
- Sep 9, 2022 (Actual)
- Last update posted
- Oct 9, 2024
2019 – 2022
United States locations
- U.S. sites
- 24
- U.S. states
- 11
- U.S. cities
- 23
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Novartis Investigative Site | Phoenix | Arizona | 85020 | — |
| Novartis Investigative Site | Huntington Beach | California | 92647 | — |
| Novartis Investigative Site | Loma Linda | California | 92354 | — |
| Novartis Investigative Site | Riverside | California | 92505 | — |
| Novartis Investigative Site | Santa Ana | California | 92705 | — |
| Novartis Investigative Site | Fort Lauderdale | Florida | 33309 | — |
| Novartis Investigative Site | Fort Myers | Florida | 33912-7125 | — |
| Novartis Investigative Site | Orlando | Florida | 32789 | — |
| Novartis Investigative Site | Pinellas Park | Florida | 33782 | — |
| Novartis Investigative Site | Winter Haven | Florida | 33880 | — |
| Novartis Investigative Site | Springfield | Illinois | 62704 | — |
| Novartis Investigative Site | Indianapolis | Indiana | 46280 | — |
| Novartis Investigative Site | West Des Moines | Iowa | 50266 | — |
| Novartis Investigative Site | Minneapolis | Minnesota | 55435 | — |
| Novartis Investigative Site | Hickory | North Carolina | 28602 | — |
| Novartis Investigative Site | Portland | Oregon | 97210 | — |
| Novartis Investigative Site | Springfield | Oregon | 97477 | — |
| Novartis Investigative Site | Germantown | Tennessee | 38138 | — |
| Novartis Investigative Site | Austin | Texas | 78705 | — |
| Novartis Investigative Site | Bellaire | Texas | 77401 | — |
| Novartis Investigative Site | Fort Worth | Texas | 76104 | — |
| Novartis Investigative Site | Houston | Texas | 77025 | — |
| Novartis Investigative Site | Houston | Texas | 77030 | — |
| Novartis Investigative Site | San Antonio | Texas | 78240 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 94 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04005352, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 9, 2024 · Synced Oct 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT04005352 live on ClinicalTrials.gov.